Invasive pulmonary aspergillosis

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 4, 2005, Pages 613-627

  Doffman, Sarah R ^a   Agrawal, Samir G ^a   Brown, Jeremy S ^b  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Amphotericin B; Azoles; Caspofungin; Exhaled breath condensate; Galactomannan; Invasive pulmonary aspergillosis; PCR

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CYCLOSPORIN; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; GALACTOMANNAN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; PHENYTOIN; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ASPERGILLUS; BONE MARROW SUPPRESSION; BRONCHOSPASM; CHILL; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; INFECTION SENSITIVITY; INJECTION PAIN; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG BIOPSY; LUNG SURGERY; MEDICAL DECISION MAKING; MICROBIOLOGY; MICROSCOPY; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PNEUMOTHORAX; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT PLANNING; UREMIA; VISUAL DISORDER; VISUAL HALLUCINATION;

ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY;

EID: 24044438474     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.4.613     Document Type: Review

References (116)

1. Latge JP. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12, 310-350 (1999).
2. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am. J. Hematol. 66, 257-262 (2001).
3. Latge JP. The pathobiology of Aspergillus fumigatus. Trends Microbiol. 9, 382-389 (2001).
4. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917 (2002).
5. Hachem RY, Kontoyiannis DP, Boktour MR et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101, 1594-1600 (2004).
6. Denning DW. Early diagnosis of invasive aspergillosis. Lancet 355, 423-424 (2000).
7. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002).
8. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur. J. Cancer Care (Engl). 10, 56-62 (2001).
9. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 34, 115-121 (2004).
10. Minari A, Husni R, Avery RK et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl. Infect. Dis. 4, 195-200 (2002).
11. O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology (Am. Soc. Hematol. Educ. Program) 438-472 (2003).
12. De Rosa FG, Shaz D, Campagna AC et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-α-neutralizing antibody: a possible healthcare-associated case? Infect. Control Hosp. Epidemiol. 24, 477-482 (2003).
13. Nenoff P, Horn LC, Mierzwa M et al. Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Mycoses 38, 467-471 (1995).
14. Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur. J. Pediatr. 161, 563-574 (2002).
15. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 121, 1988-1999 (2002).
16. Guermazi A, Benchaib N, Zagdanski AM et al. Cerebral and spinal cord involvement resulting from invasive aspergillosis. Eur. Radiol. 12, 147-150 (2002).
17. Schelenz S, Goldsmith DJ. Aspergillus endophthalmitis: an unusual complication of disseminated infection in renal transplant patients. J. Infect. 47, 336-343 (2003).
18. Paterson DL. New clinical presentations of invasive aspergillosis in nonconventional hosts. Clin. Microbiol. Infect. 10(Suppl. 1), 24-30 (2004).
19. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albos A. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemoradiotherapy. A single-center experience and review of the literature. Haematologica 82, 297-304 (1997).
20. Gorelik O, Cohen N, Shpirer I et al. Fatal haemoptysis induced by invasive pulmonary aspergillosis in patients with acute leukaemia during bone marrow and clinical remission: report of two cases and review of the literature. J. Infect. 41, 277-282 (2000).
21. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoictic stem cell transplants: an international consensus. Clin. Infect. Dis. 34, 7-14 (2002).
22. Blum U, Windfuhr M, Buitrago-Tellez C et al. Invasive pulmonary aspergillosis. MRI, CT and plain radiographic findings and their contribution for early diagnosis. Chest 106, 1156-1161 (1994).
23. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 15, 139-147 (1997).
24. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol. 19, 253-259 (2001).
25. Reichenberger F, Habicht J, Kaim A et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am. J. Respir. Crit. Care Med. 158, 885-890 (1998).
26. Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol. Immunol. 38, 947-957 (2002).
27. Reichenberger F, Habicht J, Matt P et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant. 24, 1195-1199 (1999).
28. Hayes-Jordan A, Benaim E, Richardson S et al. Open lung biopsy in pediatric bone marrow transplant patients. J. Pediatr. Surg. 37, 446-452 (2002).
29. Nosari A, Anghilieri M, Carrafiello G et al. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica 88, 1405-1409 (2003).
30. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J. Heart Lung Transplant. 22, 258-266 (2003).
31. Loeffler J, Hebart H, Brauchle U, Schumacher U, Einsele H. Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR. J. Clin. Microbiol. 38, 3830-3833 (2000).
32. Einsele H, Hebart H, Roller G et al. Detection and identification of fungal pathogens in blood by using molecular probes. J. Clin. Microbiol. 35, 1353-1360 (1997).
33. Challier S, Boyer S, Abachin E, Berche P. Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 42, 844-846 (2004).
34. Marr KA, Balajee SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J. Infect. Dis. 190, 641-649 (2004).
35. Musher B, Fredricks D, Leisenring W et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J. Clin. Microbiol. 42, 5517-5522 (2004).
36. Sulahian A, Tabouret M, Ribaud P et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur. J. Clin. Microbiol. Infect. Dis. 15, 139-145 (1996).
37. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect. Dis. 4, 349-357 (2004).
38. Herbrecht R, Letscher-Bru V. Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 20, 1898-1906 (2002).
39. Maertens J, Verhaegen J, Demuynck H et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J. Clin. Microbiol. 37, 3223-3228 (1999).
40. Walsh TJ, Shoham S, Petraitiene R et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J. Clin. Microbiol. 42, 4744-4748 (2004).
41. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan platelia aspergillus test results for patients receiving piperacillin-tazobactam. Clin. Infect. Dis. 38, 913-916 (2004).
42. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40, 1762-1769 (2005).
43. Maertens J, Van Eldere J, Verhaegen J et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J. Infect. Dis. 186, 1297-1306 (2002).
44. Sulahian A, Boutboul F, Ribaud P et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91, 311-318 (2001).
45. Maertens J, Glasmacher A, Selleslag D et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin. Infect. Dis. 41, E9-E14 (2005).
46. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis. 1, 273-283 (1999).
47. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8, 17-42 (1983).
48. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12, 308-329 (1990).
49. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin. Infect. Dis. 20, 755-761 (1995).
50. Levy M, Domaratzki J, Koren G. Amphotericin-induced heart-rate decrease in children. Clin. Pediatr. (Phila). 34, 358-364 (1995).
51. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomized controlled trial. Br. Med. J. 322, 579-582 (2001).
52. EORTC International Antimicrobial Therapy Co-operative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am. J. Med. 86, 668-672 (1989).
53. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72, 101-111 (1982).
54. Denning DW. Treatment of invasive aspergillosis. J. Infect. 28(Suppl. 1), 25-33 (1994).
55. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32, 358-366 (2001).
56. Veltri A, Anselmetti GC, Bartoli G et al. Percutaneous treatment with amphotericin B of mycotic lung lesions from invasive aspergillosis: results in 10 immunocompromised patients. Eur. Radiol. 10, 1939-1944 (2000).
57. Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10, 1570-1575 (1996).
58. Lister J. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur. J. Haematol. Suppl. 57, 18-23 (1996).
59. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12, 1147-1201 (1990).
60. Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations - Fungizone, amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis. Antimicrob. Agents. Chemother. 48, 1047-1050 (2004).
61. Groll AH, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182, 274-282 (2000).
62. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27, 603-618 (1998).
63. Bowden R, Chandrasekaf P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35, 359-366 (2002).
64. Subira M, Martino R, Gomez L et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur. J. Haematol. 72, 342-347 (2004).
65. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol. 103, 205-212 (1998).
66. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. 27, 1406-1412 (1998).
67. Sobel JD. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Clin. Infect. Dis. 39(Suppl. 4), S224-S227 (2004).
68. Sanati H, Belanger P, Fratti R, Ghannoum. M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother. 41, 2492-2496 (1997).
69. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 23, 685-693 (1996).
70. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch. Intern. Med. 162, 985-992 (2002).
71. Ducharme MP, Slaughter RL, Warbasse LH et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin. Pharmacol. Ther. 58, 617-624 (1995).
72. Kramer MR, Marshall SE, Denning DW et al. Cyclosporin and itraconazole interaction in heart and lung transplant recipients. Ann. Intern. Med. 113, 327-329 (1990).
73. Mahnke CB, Sutton RM, Venkataramanan R et al. Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr. Transplant. 7, 474-478 (2003).
74. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 696-709 (2000).
75. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin. Ther. 25, 1321-1381 (2003).
76. Kappe R. Antifungal activity of the new azole UK-109, 496 (voriconazole). Mycoses 42(Suppl. 2), 83-86 (1999).
77. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350, 950-952 (2004).
78. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin. Infect. Dis. 40, 770-771 (2005).
79. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64, 1997-2020 (2004).
80. Wingard JR, Leather H. A new era of antifungal therapy. Biol. Blood Marrow Transplant. 10, 73-90 (2004).
81. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346, 225-234 (2002).
82. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002).
83. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58, 612-624 (2004).
84. Lodge BA, Ashley ED, Steele MP. Perfect JR. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J. Clin. Microbiol. 42, 1376-1378 (2004).
85. Segal BH, Barnhart LA, Anderson VL et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. 40, 1684-1688 (2005).
86. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of ravuconazole (BMS-207147) in a guinea-pig model of disseminated aspergillosis. J. Antimicrob. Chemother. 49, 353-357 (2002).
87. Hajdu R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents. Chemother. 41, 2339-2344 (1997).
88. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin. Ther. 24, 351-377 (2002).
89. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39, 1563-1571 (2004).
90. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351, 1391-1402 (2004).
91. Perea S, Gonzalez G, Fothergill AW et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46, 3039-3041 (2002).
92. George D, Kordick D, Miniter P, Patterson TF, Andriole VT. Combination therapy in experimental invasive aspergillosis. J. Infect. Dis. 168, 692-698 (1993).
93. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46, 245-247 (2002).
94. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37(Suppl. 3), S188-S224 (2003).
95. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br. J. Haematol. 126, 165-175 (2004).
96. Kontoyiannis DP, Lewis RE, Sagar N et al. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob. Agents Chemother. 44, 2915-2918 (2000).
97. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39, 797-802 (2004).
98. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis. 37(Suppl. 3), S157-S187 (2003).
99. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 34, 205-215 (1991).
100. Abu Jawdeh L, Haidar R, Bitar F et al. Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: response to GM-CSF therapy. J. Infect. 41, 97-100 (2000).
101. Groll A, Renz S, Gerein V et al. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF). Mycoses 35, 67-75 (1992).
102. Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM. Recombinant human interferon-γ as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J. Infect. Dis. 163, 908-911 (1991).
103. Bernard A, Caillot D, Couaillier JF et al. Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann. Thorac. Surg. 64, 1441-1447 (1997).
104. Matt P, Bernet F, Habicht J et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 126, 1783-1788 (2004).
105. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin. Microbiol. Infect. 7(Suppl. 2), 54-61 (2001).
106. Habicht JM, Matt P, Passweg JR et al. Invasive pulmonary fungal infection in hematologic patients: is resection effective? Hematol. J. 2, 250-256 (2001).
107. Menotti J, Waller J, Meunier O et al. Epidemiological study of invasive pulmonary aspergillosis in a hematology unit by molecular typing of environmental and patient isolates of Aspergillus fimigatus. J. Hosp. Infect. 60, 61-68 (2005).
108. Engelhart S, Hanfland J, Glasmacher A et al. Impact of portable air filtration units on exposure of hematology-oncology patients to airborne Aspergillus fumigatus spores under field conditions. J. Hosp. Infect. 54, 300-304 (2003).
109. Hahn T, Cummings KM, Michalek AM et al. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect. Control Hosp. Epidemiol. 23, 525-531 (2002).
110. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind, placebo-controlled study. Bone Marrow Transplant. 23, 163-168 (1999).
111. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med. 138, 705-713 (2003).
112. Gallin JI, Alling DW, Malech HL et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N. Engl. J. Med. 348, 2416-2422 (2003).
113. Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94, 3230-3246 (2002).
114. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur. Respir. J. 13, 180-186 (1999).
115. Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin. Infect. Dis. 33, 1621-1627 (2001).
116. Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and analysis of exhaled breath condensate in humans. Am. J. Respir. Crit. Care Med. 164, 731-737 (2001).